Research programme: dihydrofolate reductase inhibitors - SerenexAlternative Names: DHFR inhibitors - Serenex; Dihydrofolate reductase inhibitors research programme - Serenex; SC101150; SC105530
Latest Information Update: 16 Jul 2016
At a glance
- Originator Serenex
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA
- 19 Jan 2005 Preclinical trials in Cancer in USA (unspecified route)